Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

Inclusion Criteria

• •Patients who:
• •1. Provide signed informed consent in accordance with local regulations.
• •2. Have Huntington disease including clinical features of HD and a CAG repeat number ≥ 36.
• •3. Have a Total Functional Capacity between 6 and 13, inclusive.
• •4. Have cognitive impairment as demonstrated by a MoCA score of ≥ 12.
• •5. Are ≥ 25 years of age.
• •6. If taking tetrabenazine, have been on a stable dose for at least 3 months.
• •7. If female, are either a) of childbearing potential and compliant in using adequate birth control or b) not of childbearing potential.
• •8. If male, is either a) of reproductive potential and compliant in using adequate birth control or b) not of reproductive potential.
• •9. Have a study partner who is willing to provide consent and spends on average at least two hours a day for at least four days a week with the patient, is fluent in the English language, and who agrees to attend certain study visits and provide accurate information about the patient.
• •10. Are able to swallow oral capsules.
• •11. Are fluent in the English language for the administration of rating scales and have sufficient visual, hearing and motor skills to complete procedures.